Effect of antithrombin III on glycoprotein Ib/IX/V activation in human platelets: Suppression of thromboxane A2 generation

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 87, Issue 2-3, 2012, Pages 57-62

  Doi, Tomoaki ^a   Tokuda, Haruhiko ^a,b   Matsushima Nishiwaki, Rie ^a   The Cuong, Nguyen ^a   Kageyama, Yasunari ^a   Iida, Yuko ^a   Kondo, Akira ^a,c   Akamatsu, Shigeru ^d   Otsuka, Takanobu ^c   Iida, Hiroki ^a   Kozawa, Osamu ^a   Ogura, Shinji ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^d Matsunami General Hospital   (Japan)

Author keywords

Antithrombin III; Platelet; Ristocetin; Soluble CD40 ligand; Thromboxane A2

Indexed keywords

ANTITHROMBIN III; CD40 LIGAND; GLYCOPROTEIN; GLYCOPROTEIN IB; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN IX; GLYCOPROTEIN V; MITOGEN ACTIVATED PROTEIN KINASE P38; PLATELET DERIVED GROWTH FACTOR AB; THROMBOXANE A2; THROMBOXANE B2; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL SIZE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; ENZYME RELEASE; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; METABOLITE; PARTICLE SIZE; PRIORITY JOURNAL; SECRETORY GRANULE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ANTIGENS, CD40; ANTITHROMBIN III; BLOOD PLATELETS; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET-DERIVED GROWTH FACTOR; PLATELET-RICH PLASMA; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RISTOCETIN; THROMBOXANE A2;

EID: 84865350061     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2012.05.010     Document Type: Article

References (28)

1. Bauer K.A., Rosenberg R.D. Role of antithrombin III as a regulator of in vivo coagulation. Semin. Hematol. 1991, 28:10-18.
2. Levi M., de Jonge E., van der Poll T. Sepsis and disseminated intravascular coagulation. J. Thromb. Thrombolysis 2003, 16:43-47.
3. Buller H.R., ten Cate J.W. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. Am. J. Med. 1989, 87:44S-48S.
4. Triantaphyllopoulos D.C. Effects of human antithrombin III on mortality and blood coagulation induced in rabbits by endotoxin. Thromb. Haemostasis 1984, 51:232-235.
5. Vinazzer H. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Semin. Thromb. Hemostasis 1989, 15:347-352.
6. Kaneider N.C., Feistritzer C., Gritti D., Mosheimer B.A.B.A., Ricevuti G., Patsch J.R., Wiedermann C.J. Expression and function of syndecan-4 in human platelets. Thromb. Haemostasis 2005, 93:1120-1127.
7. Doi T., Adachi S., Takai S., Matsushima-Nishiwaki R., Kato H., Enomoto Y., Minamitani C., Otsuka T., Tokuda H., Akamatsu S., Iwama T., Kozawa O., Ogura.S. Antithrombin III suppresses ADP-induced platelet granule secretion: inhibition of HSP27 phosphorylation. Arch. Biochem. Biophys. 2009, 489:62-67.
8. Doi T., Adachi S., Matsushima-Nishiwaki R., Kato H., Enomoto Y., Natsume H., Kato K., Mizutani J., Otsuka T., Tokuda H., Akamatsu S., Iwama T., Kozawa O., Ogura.S. Antithrombin III reduces collagen-stimulated granule secretion of PDGF-AB and the release of soluble CD40 ligand from human platelets. Int. J. Mol. Med. 2010, 26:387-392.
9. Berndt M.C., Shen Y., Dopheide S.M., Gardiner E.E., Andrews.R.K. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb. Haemostasis 2001, 86:178-188.
10. Garcia A., Quinton T.M., Dorsam R.T., Kunapuli S.P. Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelets. Blood 2005, 106:3410-3414.
11. Dong J.F., Berndt M.C., Schade A., McIntire L.V., Andrews R.K., López.J.A. Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions. Blood 1996, 97:162-168.
12. 2 promotes soluble CD40 ligand release from human platelets. Atherosclerosis 2010, 209:415-421.
13. Ward C.M., Andrew R.K., Smith A.O., Berndt.M.C. Mocharhagin, novel cobra venom mettaloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Iα. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Iα as a binding site for von Willebrand factor and α-thrombin. Biochemistry 1996, 35:4929-4938.
14. Fabre J.E., Nguyen M., Latour A., Keifer J.A., Audoly L.P., Coffman T.M., Koller B.H. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat. Med. 1995, 5:1199-1202.
15. Kato K., Ito H., Hasegawa K., Inaguma Y., Kozawa O., Asano T. Modulation of the stress-induced synthesis of hsp27 and alpha B-crystallin by cyclic AMP in C6 rat glioma cells. J. Neurochem. 1996, 66:946-950.
16. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage. Nature 1970, 227:680-685.
17. Catella F., Healy D., Lawson J.A., FitzGerald G.A. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc. Natl. Acad. Sci. USA 1986, 83:5861-5865.
18. Bertele V., Di Minno G., de Gaetano G. U-46619, a stable analogue of prostaglandin H2, induces retraction of human platelet-rich plasma clots. Thromb. Res. 1980, 18:543-545.
19. Nakahata.N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol. Ther. 2008, 118:18-35.
20. Davi G., Patrone C. Platelet activation and atherothrombosis. N. Engl. J. Med. 2007, 357:2482-2492.
21. Hermann A., Rauch B.H., Braun M., Schror K., Weber A.A. Platelet CD40 ligand [CD40L]--subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001, 12:74-82.
22. Andre P., Nannizzi-Alaimo L., Prasad S.K., Phillips.D.R. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002, 106:896-899.
23. Henn V., Slupsky J.R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G., Kroczek.R.A. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391:591-594.
24. Heeschen C., Dimmeler S., Hamm C.W., van den Brand M.J., Boersma E., Zeiher A.M. M.L. Simoons. Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. 2003, 348:1104-1111.
25. Varo N., de Lemos J.A., Libby P., Morrow D.A., Murphy S.A., Nuzzo R., Gibson C.M., Cannon C.P., Braunwald E., Schonbeck U. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003, 108:1049-1052.
26. Lopez J.A., Dong J.F. Structure and function of the glycoprotein Ib-IX-V complex. Curr. Opin. Hematol. 1997, 4:323-329.
27. Kroll M.H., Hellums J.D., Mclntire L.V., Schafer A.I., Moake J.L. Platelets and shear stress. Blood 1996, 88:1525-1541.
28. Malek A.M., Alper S.L., Izumo S. Hemodynamic shear stress and its role in atherosclerosis. J. Am. Med. Assoc. 1999, 282:2035-2042.